- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
NeuralCIM (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7155;
Among participants with mild-moderate Alzheimer's disease clinical syndrome, neuroEPO plus improved the cognitive evaluation at 48 Background: NeuroEPO (NeuralCIM
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
NeuralCIM (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5089;
Background: NeuroEPO (NeuralCIM Background: NeuroEPO (NeuralCIM
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
NeuralCIM (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_2843;
Background: NeuroEPO (NeuralCIM Background: NeuroEPO (NeuralCIM
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
NeuralCIM (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_623;
Background: NeuroEPO (NeuralCIM Background: NeuroEPO (NeuralCIM
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
NEUROEPO IN NEURODEGENERATIVE DISORDERS (ONSITE - HALL G3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_963;
No serious adverse events related with NeuroEPO were reported. Conclusions NeuroEPO improved clinical outcomes with a good safety profile in patients with SCA2, PD and mild-to-moderate Alzheimer's clinical syndrome.
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
Journal: The Effect of Neuroepo on Cognition in Parkinson's Disease Patients Is Mediated by Electroencephalogram Source Activity. (Pubmed Central) - Jul 20, 2022
P1/2
A combined mediation model showed that 66% of the total effect of the cognitive improvement was mediated by qEEG (p = 0.0001), with the remaining direct effect between dose and Cognition (p = 0.002), due to other causes. These results suggest that Neuroepo has a positive influence on Cognition in PD patients and that a large portion of this effect is mediated by brain mechanisms reflected in qEEG.
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
Journal: Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis. (Pubmed Central) - Apr 6, 2022
Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products. The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
NEUROEPO IN MILD-TO-MODERATE ALZHEIMER’S CLINICAL SYNDROME. PHASE 2-3 CONTROLLED CLINICAL TRIAL () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1364;
The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases. Overall NeuroEPO significantly improved clinical outcomes with a good safety profile in patients with mild-to-moderate Alzheimer’s clinical syndrome.
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
Clinical, Journal: Short-term Tolerance of Nasally-administered NeuroEPO in Patients with Parkinson Disease. (Pubmed Central) - Nov 10, 2021
P1/2
Overall NeuroEPO significantly improved clinical outcomes with a good safety profile in patients with mild-to-moderate Alzheimer’s clinical syndrome. Nasally administered NeuroEPO for five weeks in patients with Parkinson disease stages 1 and 2 on Hoehn & Yahr Scale is well tolerated.
- |||||||||| NeuroEPO (recombinant human erythropoietin with low sialic acid) / CIMAB
Preclinical, Journal: Detection of a non-erythropoietic EPO, Neuro-EPO, in blood after intra-nasal administration in rat. (Pubmed Central) - Oct 2, 2021
Surprisingly, brain extracts did not show the presence of Neuro-EPO even 2 hours after administration, indicating a fast degradation or elimination from the brain to the bloodstream. This experiment indicated that detection of Neuro-EPO after intranasal delivery should be possible for a few days.
|
